Assessing physician perception of patients with rheumatoid arthritis (RA) they consider as Infliximab-biosimilar-suitable\nmay provide insights into eventual biosimilar adoption in clinical practice settings in Europe. Medical charts of 1204 patients with\nrheumatoid arthritis (RA) from UK/France/Germany/Italy/Spain were abstracted; 425 were identified by physicians as biosimilarinfliximab-\nsuitable; of these, 55% were identified as candidates for being prescribing biosimilar-infliximab. For biosimilar-infliximabsuitable\nYes/No groups, time since diagnosis: 67.1/85.3mo; percentage with moderate/severe disease (per physician judgment):\n46%/40%; ESR:23.4/21.2mm/h; CRP:12.6/8.1mg/dl;VAS(0-10scale):3.7/3.4; Swollen Joint Count:2.6/1.9 and Tender Joint\nCount:4.4/3.1. RA patients considered infliximab-biosimilar not-suitable (per clinical judgment) had been in care for relatively longer\nperiod, had relatively lower disease severity and were less involved in treatment decisions. Physicians were also not readily prepared to\nprescribe the biosimilar to all infliximab-biosimilar-suitable RA patients. Drivers behind observed physician perception warrant\nscrutiny.
Loading....